Literature DB >> 6639832

Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine.

A Quattrone, G Tedeschi, U Aguglia, F Scopacasa, G F Direnzo, L Annunziato.   

Abstract

Acute oral administration of various doses of fenfluramine, a 5-HT releaser, induced a dose-related increase of PRL secretion in nine healthy volunteers. Fenfluramine reached the maximum effect on PRL secretion at 4 h after its administration. This effect was already significant at 2 h and lasted till 8 h. Metergoline, a 5-HT receptor blocker, when administered alone, decreased serum PRL levels in six healthy subjects. The pretreatment with this drug significantly antagonized the PRL-releasing action of fenfluramine (60 mg) suggesting that the effect of fenfluramine on PRL release may be mediated through a 5-HT mechanism in the brain. These findings suggest the possibility that serum PRL levels in humans may represent a useful tool to evaluate, in vivo, the activity of drugs possessing putative 5-hydroxytryptaminergic properties.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6639832      PMCID: PMC1428066          DOI: 10.1111/j.1365-2125.1983.tb02202.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  De- and regeneration of brain serotonin neurons following 5,7-dihydroxytryptamine treatment: effects on serum LH, FSH and prolactin levels in male rats.

Authors:  W Wuttke; A Björklund; H G Baumgarten; L Lachenmayer; M Fenske; H P Klemm
Journal:  Brain Res       Date:  1977-10-07       Impact factor: 3.252

2.  Effects of serotonin precursors and melatonin on serum prolactin release in rats.

Authors:  K H Lu; J Meites
Journal:  Endocrinology       Date:  1973-07       Impact factor: 4.736

3.  A homologous radioimmunoassay for human prolactin.

Authors:  Y N Sinha; F W Selby; U J Lewis; W P VanderLaan
Journal:  J Clin Endocrinol Metab       Date:  1973-03       Impact factor: 5.958

4.  Evaluation of the peripheral and central antagonistic activities against 5-hydroxytryptamine of some new agents.

Authors:  C Mawson; H Whittington
Journal:  Br J Pharmacol       Date:  1970-05       Impact factor: 8.739

5.  Effect of midbrain raphe lesion or 5,7-dihydroxytryptamine treatment on the prolactin-releasing action of quipazine and D-fenfluramine in rats.

Authors:  A Quattrone; G Schettini; G di Renzo; G Tedeschi; P Preziosi
Journal:  Brain Res       Date:  1979-09-28       Impact factor: 3.252

6.  Pharmacological evidence of an interaction between serotonergic and dopaminergic neurons in the control of prolactin secretion in male rats.

Authors:  A Quattrone; G Schettini; G F Di Renzo; P Preziosi
Journal:  Arch Int Pharmacodyn Ther       Date:  1979-03

7.  Failure of L-tryptophan to stimulate prolactin secretion in man.

Authors:  R H Wiebe; S Handwerger; C B Hammond
Journal:  J Clin Endocrinol Metab       Date:  1977-12       Impact factor: 5.958

8.  Inhibition of prolactin release by serotonin antagonists in hyperprolactinemic subjects.

Authors:  C Ferrari; R Caldara; P Rampini; P Telloli; M Romussi; A Bertazzoni; G Polloni; A Mattei; P G Crosignani
Journal:  Metabolism       Date:  1978-10       Impact factor: 8.694

9.  Neuroendocrine effects of quipazine in man in health state or with neurological disorders.

Authors:  E A Parati; P Zanardi; D Cocchi; T Caraceni; E E Müller
Journal:  J Neural Transm       Date:  1980       Impact factor: 3.575

10.  Suppression of puerperal lactation by metergoline.

Authors:  P G Crosignani; G C Lombroso; A Caccamo; E Reschini; M Peracchi
Journal:  Obstet Gynecol       Date:  1978-01       Impact factor: 7.661

View more
  14 in total

1.  Does metergoline selectively attenuate 5-HT mediated prolactin release?

Authors:  P M Ellis; S E Gartside; C J Ware; G M Campling; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome.

Authors:  A M Bakheit; P O Behan; T G Dinan; C E Gray; V O'Keane
Journal:  BMJ       Date:  1992-04-18

3.  Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.

Authors:  M Koulu; M Scheinin; A Kaarttinen; J Kallio; K Pyykkö; J Vuorinen; R H Zimmer
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

4.  5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects.

Authors:  E F Coccaro; R J Kavoussi; T B Cooper; R Hauger
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

5.  Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

6.  Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers.

Authors:  E M Goodall; P J Cowen; M Franklin; T Silverstone
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  The emerging modern face of mood disorders: a didactic editorial with a detailed presentation of data and definitions.

Authors:  Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2010-04-12       Impact factor: 3.455

8.  5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects.

Authors:  E F Coccaro; R J Kavoussi; M Oakes; T B Cooper; R Hauger
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

9.  Serotonergic responses in depressed patients with or without a history of alcohol use disorders and healthy controls.

Authors:  Leo Sher; Barbara H Stanley; Thomas B Cooper; Kevin M Malone; J John Mann; Maria A Oquendo
Journal:  Eur Neuropsychopharmacol       Date:  2008-06-30       Impact factor: 4.600

10.  The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes.

Authors:  Beatrice A Golomb; Michael H Criqui; Halbert L White; Joel E Dimsdale
Journal:  Control Clin Trials       Date:  2004-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.